These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2407675)

  • 41. Corporate responsibility for recombinant DNA activities.
    Berger BA
    Univ Toledo Law Rev; 1981; 12(4):913-24. PubMed ID: 11649592
    [No Abstract]   [Full Text] [Related]  

  • 42. U.S. budget. Democratic Congress begins to put its stamp on science.
    Kintisch E
    Science; 2007 Jun; 316(5833):1828-9. PubMed ID: 17600191
    [No Abstract]   [Full Text] [Related]  

  • 43. The decline in U.S. cancer mortality from 1991 to 1995: what's behind the numbers?
    Clapp RW
    Int J Health Serv; 1998; 28(4):747-55. PubMed ID: 9842497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carcinogens. Lashed by critics, WHO's cancer agency begins a new regime.
    Ferber D
    Science; 2003 Jul; 301(5629):36-7. PubMed ID: 12843372
    [No Abstract]   [Full Text] [Related]  

  • 45. Mold.
    Smith JA
    NCSL Legisbrief; 2003; 11(45):1-2. PubMed ID: 14610757
    [No Abstract]   [Full Text] [Related]  

  • 46. The U.S. EPA Conference on Preventable Causes of Cancer in Children: a research agenda.
    Carroquino MJ; Galson SK; Licht J; Amler RW; Perera FP; Claxton LD; Landrigan PJ
    Environ Health Perspect; 1998 Jun; 106 Suppl 3(Suppl 3):867-73. PubMed ID: 9646050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Volleys in the cancer war. Has the 30-year enterprise been wrongheaded from the start?
    Sobel RK
    US News World Rep; 2001 Jun; 130(24):42-3. PubMed ID: 11430211
    [No Abstract]   [Full Text] [Related]  

  • 48. Update of potency factors for asbestos-related lung cancer and mesothelioma.
    Berman DW; Crump KS
    Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cancer prevention in the workplace and natural environment. A review of etiology, research design, and methods of risk reduction.
    Swanson GM
    Cancer; 1988 Oct; 62(8 Suppl):1725-46. PubMed ID: 3048635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preventive oncology and the National Cancer Program.
    Wynder EL
    Prev Med; 1980 Nov; 9(6):823-5. PubMed ID: 7454705
    [No Abstract]   [Full Text] [Related]  

  • 51. Legislative proposals for reversing the cancer epidemic and controlling run-away industrial technologies.
    Epstein SS
    Int J Health Serv; 2000; 30(2):353-71. PubMed ID: 10862380
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Man-made vitreous fibres.
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
    IARC Monogr Eval Carcinog Risks Hum; 2002; 81():1-381. PubMed ID: 12458547
    [No Abstract]   [Full Text] [Related]  

  • 53. Critical assessment of carcinogenic risk policy.
    Flamm WG
    Regul Toxicol Pharmacol; 1989 Jun; 9(3):216-24. PubMed ID: 2756168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence of political interference / EPA air pollution decision threatens public health: science disregarded, misrepresented on particulate matter standard.
    Union of Concerned Scientists
    New Solut; 2007; 17(1-2):7-11. PubMed ID: 17434854
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention of occupational cancer--toward an integrated program of governmental action.
    Lassiter DV
    Ann N Y Acad Sci; 1976; 271():214-5. PubMed ID: 1069505
    [No Abstract]   [Full Text] [Related]  

  • 56. Cancer risk assessment: importance of identifying mechanisms of action.
    Bull RJ
    J Am Water Works Assoc; 1990 Oct; 82(10):57-60. PubMed ID: 11538297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Getting it right: BPA and the difficulty proving environmental cancer risks.
    Fillon M
    J Natl Cancer Inst; 2012 May; 104(9):652-5. PubMed ID: 22517989
    [No Abstract]   [Full Text] [Related]  

  • 58. Reassessment of MTBE cancer potency considering modes of action for MTBE and its metabolites.
    Bogen KT; Heilman JM
    Crit Rev Toxicol; 2015; 45 Suppl 1():1-56. PubMed ID: 26414780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Healthy communities: reducing cancer risks.
    Bondurant E; Hanson K
    NCSL Legisbrief; 2009; 17(27):1-2. PubMed ID: 19526655
    [No Abstract]   [Full Text] [Related]  

  • 60. Major issues raised by the OMB report from the perspective of the regulatory agencies.
    Barnard RC
    Regul Toxicol Pharmacol; 1991 Dec; 14(3):223-8. PubMed ID: 1771265
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.